KRAS and colorectal carcinoma: Critically, SRC is a validated target in KRAS-mutant CRC,23 PDAC22,24 and NSCLC22,25 and it is known that G12CKRAS and SRC inhibitors work synergistically to inhibit G12CKRAS NSCLC cell proliferation.26